Harrow, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Harrow, Inc. (HROW) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.52 million as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-03-27
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.52M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.06M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $945.00K.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.64M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2024-12-31 | $1.52M 10-K · filed 2025-03-27 | |
| 2023-12-31 | $1.06M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $945.00K 10-K · filed 2024-03-19 | |
| 2021-12-31 | $4.64M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $4.02M 10-K · filed 2022-03-10 | |
| 2019-12-31 | $3.53M 10-K · filed 2021-03-08 | |
| 2018-12-31 | $3.04M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $2.53M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $3.88M 10-K · filed 2018-03-08 | |
| 2015-12-31 | $3.00M 10-K · filed 2017-03-21 | $3.24M 10-K · filed 2016-03-23 |
| 2014-12-31 | $2.65M 10-K · filed 2015-03-12 | |
| 2013-12-31 | $2.65M 10-K · filed 2016-03-23 | $2.25M 10-K · filed 2014-03-28 |
| 2012-12-31 | $1.37M 10-K · filed 2014-03-28 | |
| 2011-12-31 | $743.79K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |